1. Home
  2. BHVN vs ETNB Comparison

BHVN vs ETNB Comparison

Compare BHVN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BHVN
  • ETNB
  • Stock Information
  • Founded
  • BHVN 2013
  • ETNB 2018
  • Country
  • BHVN United States
  • ETNB United States
  • Employees
  • BHVN N/A
  • ETNB N/A
  • Industry
  • BHVN Biotechnology: Pharmaceutical Preparations
  • ETNB Biotechnology: Pharmaceutical Preparations
  • Sector
  • BHVN Health Care
  • ETNB Health Care
  • Exchange
  • BHVN Nasdaq
  • ETNB Nasdaq
  • Market Cap
  • BHVN 1.5B
  • ETNB 1.5B
  • IPO Year
  • BHVN 2017
  • ETNB 2019
  • Fundamental
  • Price
  • BHVN $15.66
  • ETNB $9.43
  • Analyst Decision
  • BHVN Strong Buy
  • ETNB Strong Buy
  • Analyst Count
  • BHVN 14
  • ETNB 8
  • Target Price
  • BHVN $54.62
  • ETNB $26.29
  • AVG Volume (30 Days)
  • BHVN 2.3M
  • ETNB 1.5M
  • Earning Date
  • BHVN 08-11-2025
  • ETNB 08-07-2025
  • Dividend Yield
  • BHVN N/A
  • ETNB N/A
  • EPS Growth
  • BHVN N/A
  • ETNB N/A
  • EPS
  • BHVN N/A
  • ETNB N/A
  • Revenue
  • BHVN N/A
  • ETNB N/A
  • Revenue This Year
  • BHVN N/A
  • ETNB N/A
  • Revenue Next Year
  • BHVN $1,007.82
  • ETNB N/A
  • P/E Ratio
  • BHVN N/A
  • ETNB N/A
  • Revenue Growth
  • BHVN N/A
  • ETNB N/A
  • 52 Week Low
  • BHVN $12.79
  • ETNB $4.16
  • 52 Week High
  • BHVN $55.70
  • ETNB $11.84
  • Technical
  • Relative Strength Index (RSI)
  • BHVN 56.24
  • ETNB 50.08
  • Support Level
  • BHVN $14.23
  • ETNB $8.82
  • Resistance Level
  • BHVN $16.14
  • ETNB $9.56
  • Average True Range (ATR)
  • BHVN 0.86
  • ETNB 0.54
  • MACD
  • BHVN 0.10
  • ETNB 0.04
  • Stochastic Oscillator
  • BHVN 85.48
  • ETNB 53.13

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Share on Social Networks: